ClinicalTrials.gg
Active, not recruitingNCT02205762Updated Nov 10, 2026

LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis

A Phase 2/3 interventional study of Prednisone and Vinblastine in Langerhans Cell Histiocytosis, sponsored by North American Consortium for Histiocytosis. Active, not recruiting at 42 sites in United States. Open to participants aged Up to 18 Years. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by North American Consortium for Histiocytosis · Phase 2/3, Interventional, and Treatment

How we know

Updated Nov 10, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
1,400
Allocation
Randomized
Ages
Up to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 47 studies in Histiocytosis, Langerhans-Cell with a site in United States — 8 open to participants now, 25 under way, 2 of them phase 3. Histiocytosis, Langerhans-Cell · United States.

Enrollment
Largest of 40
1,400 · median 21
Started
2016
with 2 others
Phase 2/3
2 of 47
none open now
Primary completion
2031-11
later than 23 of 24 live
Registered
17th of 47
by date

Among the 47 studies in Histiocytosis, Langerhans-Cell with a site in United States, this one has the largest enrollment of the 40 interventional ones that give a count, is one of 3 that started in 2016, is one of 2 in phase 2/3, reaches primary completion later than 23 of the 24 other live ones, and was the 17th registered.

Histiocytosis, Langerhans-Cell

81 studies on the registry are indexed under Histiocytosis, Langerhans-Cell; 23 are open to participants now.

Browse Histiocytosis, Langerhans-Cell studies →

Open to participants now

8 of the 47 studies in Histiocytosis, Langerhans-Cell with a site in United States are open now. Recruiting first, the newest first:

3 more — sign in →

All 8 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 19 Histiocytosis, Langerhans-Cell studies recruiting now, 8 (42%) set no upper age limit and 10 (53%) stop at 75 or younger; 13 take children under 18; 1 takes healthy volunteers.

This study: Up to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 47 studies in Histiocytosis, Langerhans-Cell with a site in United States, or all of them as a file.
02

Study summary

The LCH-IV is an international, multicenter, prospective clinical study for pediatric Langerhans Cell Histiocytosis LCH (age \< 18 years).

Read the detailed description

The international efforts of the past 20 years have shown that combination therapy with vinblastine and prednisone is an effective therapy for Multi-system (MS)-LCH. The previous prospective trial LCH-III confirmed this regimen as a standard regimen for MS-LCH in patients with and without risk organ involvement. It also showed that prolonged treatment in the latter group (treatment duration of 12 vs. 6 months) is superior in preventing disease reactivations. The results of this trial are encouraging and serve as a basis for the LCH-IV study design.Due to the complexity of the disease presentations and outcomes, the LCH-IV study seeks to tailor treatment based on features at presentation and on response to treatment, leading to seven strata:

  • Stratum I: First-line treatment for MS-LCH patients (Group 1) and patients with Single system (SS)-LCH with multifocal bone or "Central Nervous System (CNS)-risk" lesions (Group 2)
  • Stratum II: Second-line treatment for non-risk patients (patients without risk organ involvement who fail first-line therapy or have a reactivation after completion of first-line therapy)
  • Stratum III: Salvage treatment for risk LCH (patients with dysfunction of risk organs who fail first-line therapy)
  • Stratum IV: Stem cell transplantation for risk LCH (patients with dysfunction of risk organs who fail first-line therapy)
  • Stratum V: Monitoring and treatment of isolated tumorous and neurodegenerative CNS-LCH
  • Stratum VI: Natural history and management of "other" SS-LCH (patients who do not need systemic therapy at the time of diagnosis)
  • Stratum VII: Long-term Follow up (all patients irrespective of previous therapy will be followed for reactivation or permanent consequences once complete disease resolution has been achieved and the respective protocol treatment completed)
03

Conditions studied

  • Langerhans Cell Histiocytosis

Keywords

  • Langerhans cell histiocytosis
04

Who can participate

Ages eligible
Up to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Stratum I

    • Patients must be less than 18 years of age at the time of diagnosis.
    • Patients must have histological verification of the diagnosis of Langerhans cell histiocytosis according to the criteria described in Section 6.1
    • Signed form
  • Stratum II

    • Patients of Stratum I who have:
    • Progressive disease (AD worse) in non-risk organs after 6 weeks (Initial Course
    • AD intermediate or worse in non-risk organs or AD better in risk organs after 12 weeks (Initial Course 2)
    • Disease progression (AD worse) in non-risk organs at any time during continuation treatment
    • Active disease at the end of Stratum I treatment
    • Disease reactivation in non-risk organs at any time after completion of Stratum I treatment
  • Stratum III

    • Patients from Stratum I who fulfill the following criteria:
    • AD worse in risk organs after week 6 (after Initial Course 1), or AD worse or AD intermediate in risk organs after week 12 (after Initial Course 2).
    • Presence of unequivocally severe organ dysfunction at the above mentioned evaluation points (hematological dysfunction, liver dysfunction, or both of them) as

      • \<70 g/L (\<7.0 g/dl) and/or transfusion dependency
      • \<20 x109/L (20,000/μL) and/or transfusion dependency (both criteria have to be fulfilled) AND/OR
      • Liver dysfunction (or digestive involvement with protein loss)
      • Total protein \<55 g/L or substitution dependency
      • Albumin \<25 g/L or substitution dependency (at least one of the two criteria to be fulfilled)
  • Stratum IV

    • Patients from Stratum I or Stratum III who fulfill the following criteria:
    • AD worse in risk organs after week 6 (after Initial Course 1), or AD worse or AD intermediate in risk organs after week 12 (after Initial Course 2) of Stratum I OR
    • AD worse after the 2nd and 3rd 2-CdA/Ara-C course, and those AD worse or AD intermediate after the 4th 2-CdA/Ara-C course of Stratum III AND
    • Presence of unequivocally severe organ dysfunction at the above mentioned evaluation points (hematological dysfunction, liver dysfunction, or both of them) as defined in Table XI (see Section 10.3.1).
    • Informed consent: All patients or their legal guardians (if the patient is \<18 years of age) must sign an Ethics or institutional Review Board approved consent form indicating their awareness of the nature and the risks of this study. When appropriate, younger patients will be included in all discussions in order to obtain assent.
    • Adequate organ function: Patients should have adequate hepatic, renal, cardiac and pulmonary function to undergo reduced intensity HCT based upon local institutional guidelines, or at a minimum meet requirements noted in eligibility checklist Appendix A-VIII_1. However, significant hepatic and pulmonary dysfunction, if secondary to underlying LCH disease activity, will not exclude patients from protocol enrollment and should be discussed with the National PI Coordinator and the Coordinating Principal Investigator.
  • Stratum V

    • All patients with verified diagnosis of LCH and MRI findings consistent with ND-CNSLCH irrespective of previous treatments (also those not registered to other Strata ofLCH-IV).
    • Patients with isolated tumorous CNS-LCH (including isolated DI with mass lesion in the hypothalamus-pituitary axis). In patients with already established diagnosis of LCH and radiologic finding of CNS lesions compatible with LCH, a of the lesion is not obligatory. In all other cases a biopsy of the lesion is needed for inclusion into the study
  • Stratum VI

    -- Patients with newly diagnosed SS-LCH and localization other than "multifocal bone",isolated tumorous CNS lesion, or isolated "CNS-risk" lesion.

  • Stratum VII -- All patients registered in LCH IV (regardless of treatment) as long as consent for longterm follow-up has not been withheld.

Exclusion criteria

Exclusion Criteria:

  • Stratum I

    • Pregnancy (patients of child-bearing age must be appropriately tested before chemotherapy)
    • LCH-related permanent consequences (e.g. vertebra plana, sclerosing cholangitis, lung fibrosis, etc.) in the absence of active disease
    • Prior systemic therapy
  • Stratum II

    • Patients with progressive disease in risk organs
    • Permanent consequences (e.g. sclerosing cholangitis, lung fibrosis, etc.) without evidence of active LCH in the same organ or in any other locations
    • No written consent of the patient or his/her parents or legal guardian
  • Stratum III

    • The presence of any of the following criteria will exclude the patient from the study:
    • Isolated sclerosing cholangitis without evidence of active hepatic LCH as the only evidence of risk organ involvement.
    • Inadequate renal function as defined by serum creatinine > 3x normal for age
  • Stratum IV

    • Pulmonary failure (requiring mechanical ventilation) not due to active LCH.
    • Isolated liver sclerosis or pulmonary fibrosis, without active LCH.
    • Uncontrolled active life-threatening infection.
    • Decreased renal function with a of less than 50ml/1.73m2/min.
    • Pregnancy or active breast feeding
    • Failure to provide signed
  • Stratum VI

    • Patients with SS-LCH who have an isolated tumorous CNS lesion (they are eligible for Stratum V),
    • Patients with isolated "CNS-risk" or multifocal bone lesions (they are eligible for Stratum I, Group 2)
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,400 participants (actual)

Study arms

  • Experimental
    Stratum I

    Stratum I The combination of Prednisone and vinblastine is the standard first-line combination for patients needing systemic therapy (Stratum I). Patients with MS-LCH and involvement of risk organs, who do not respond to 6-12 weeks of standard therapy, will be immediately switched to alternative treatment approaches (Stratum III or Stratum IV). Further therapy prolongation (12 vs. 24 months) and intensification (± mercaptopurine) will further reduce the reactivation rate and the permanent consequences.

    Drug: Prednisone · Drug: Vinblastine · Drug: mercaptopurine

  • Experimental
    Stratum II

    A uniform "intensive" 24-week course consisting of prednisolone, vincristine and cytosine-arabinoside will be introduced in Stratum II for eligible patients. It will be followed by a continuation therapy to total treatment duration of 24 months. Participants who after SL-IT (week 24) have a response (NAD or AD better) are eligible for randomization between the continuation arms "INDOMETHACIN" and "6-MP/MTX" (mercaptopurine and Methotrexate).

    Drug: Prednisone · Drug: Vinblastine · Drug: mercaptopurine · Drug: INDOMETHACIN · Drug: Methotrexate · Drug: Cytosine Arabinoside

  • Experimental
    Stratum III

    Salvage treatment for risk LCH To assess the efficacy of the combination 2-CdA/Ara-C (Cytosine Arabinoside and 2-chlorodeoxyadenosine) in MS-LCH (patients with risk organ involvement, who fail to respond to front-line (Stratum I) therapy. The initial therapy consists of 2 courses of 2-CdA/Ara-C. Continuation of outlined treatment to be assessed at assigned intervals in each stratum.

    Drug: 2-chlorodeoxyadenosine

  • Experimental
    Stratum IV

    To determine the overall and disease free survival at 1 and 3 years after reduced intensity conditioning hematopoietic stem cell transplantation (RIC-HSCT). Salvage treatment option for MS-LCH patients with risk organ involvement, who fail to respond to front-line therapy (Stratum I) OR to the salvage 2- CdA/Ara-C regimen (Stratum III).

    Procedure: hematopoietic stem cell transplantation (RIC-HSCT)

  • Experimental
    Stratum V

    Stratum V Monitoring and Treatment of isolated tumorous and neurodegenerative CNS-LCH \- Special regimens will be offered to patients with isolated tumorous CNS-LCH (repeated 2-CdA courses) and to patients with clinically manifested ND-CNS-LCH (+/- extracranial LCH manifestations). For the last group monotherapy with Ara-C courses or (Intravenous immunoglobulin)IVIG will be offered depending on physician's choice.

    Drug: Cytosine Arabinoside · Drug: 2-chlorodeoxyadenosine · Biological: Intravenous immunoglobulin

  • Experimental
    Stratum VI

    Natural history and management of "other" SS-LCH not eligible for stratum I group 2. * Treatment Options- Management (mostly "wait \& see" and topical treatment) is left to the discretion of the treating physician. All treatments and disease responses must be reported in the database. In the case of uncertainties please contact your National Coordinator. * Patients being followed on Stratum VI who have progression of disease to MSLCH, multifocal bone disease or CNS-risk bone lesions should be enrolled on Stratum I therapy. * Patients being followed on Stratum VI who develop isolated tumorous or neurodegenerative CNS-LCH should be enrolled on Stratum V.

    Drug: Prednisone · Drug: Vinblastine · Drug: mercaptopurine · Drug: Cytosine Arabinoside · Drug: 2-chlorodeoxyadenosine · Biological: Intravenous immunoglobulin

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Patients with Reactivation Free Survival

    Stratum I, II, VI

    Time frame: 12 Months

  2. Response Rate of Second Cycle

    Stratum III

    Time frame: 9 weeks

  3. Overall and disease free survival at 1 and 3 years after reduced intensity conditioning hematopoietic stem cell transplantation (RIC-HSCT)

    Stratum IV

    Time frame: 3 Years

  4. The cumulative incidence of radiological and clinical neurodegeneration in patients with isolated tumorous CNS-LCH, DI, anterior pituitary dysfunction, and those with CNS-risk lesions

    Stratum V

    Time frame: 2 Years

  5. The time interval and cumulative incidence of progression of radiological neurodegeneration to clinically manifested ND-CNS-LCH

    Stratum V

    Time frame: 2 Years

  6. Cumulative incidence of specific Permanent Consequences e.g. diabetes insipidus (DI), growth hormone deficiency (GHD), neuropsychological impairment, etc.

    From all treatment stratum via long-term follow up in Stratum VII

    Time frame: 2 Years

Secondary outcomes

  1. Overall Survival

    Stratum I

    Time frame: 2 Years

  2. Number of Participants with Serious and Non-Serious Adverse Events

    Time frame: 2 Years

  3. Incidence of Permanent Consequences

    All Stratum

    Time frame: 2 Years

  4. Cumulative incidence of reactivations in risk organs

    Time frame: 2 Years

  5. Time to complete disease resolution

    Stratum III

    Time frame: 2 Years

  6. Response rate to the combination of prednisone, vincristine and cytarabine

    Stratum II

    Time frame: 2 years

  7. The proportion of patients alive and free of disease without permanent consequences (e.g. diabetes insipidus, anterior pituitary dysfunction, radiological or clinical neurodegeneration)

    Stratum II

    Time frame: 2 Years

  8. Percentage of treatment-related toxicities

    Stratum II

    Time frame: 2 Years

  9. Reactivation rates after continuation treatment with Indomethacin vs. 6-MP/MTX.

    Stratum II

    Time frame: 2 years

  10. The type of subsequent intensive and/or maintenance therapy utilized

    Stratum III

    Time frame: 2 Years

  11. Early and late mortality

    Stratum II

    Time frame: 2 Years

  12. Early and late toxicity

    Stratum III

    Time frame: 2 Years

  13. d+100 transplant related mortality

    Stratum IV

    Time frame: 2 Years

  14. Incidence of hematopoietic recovery, and donor chimerism at d+100 and 1 year post RIC-HSCT

    Time frame: 2 Years

  15. Record all occurrence of skin, GI or liver abnormalities fulfilling criteria of Grades II-IV acute GVHD

    Stratum IV: Hematopoetic Stem Cell Transplantation for Risk LCH

    Time frame: 2 Years

  16. Percentage of Participants with incidence of chronic GVHD

    Stratum IV

    Time frame: 2 Years

  17. Response Rate to ND-CNS-targeted therapy at 12 and 24 months after start of therapy

    Stratum V

    Time frame: 2 years

  18. Response of isolated tumorous CNS-LCH to 2-CDA

    Stratum V

    Time frame: 2 Years

  19. Frequency of ND-CNS-LCH in patients with isolated tumorous CNS-LCH

    Stratum V

    Time frame: 2 Years

  20. Methods of early identification of ND-CNS-LCH

    Stratum V - Exploration of the value of neurochemistry, neurophysiology, and neuropsychology methods in early identification of ND-CNS-LCH and in assessing its severity, and comparison to MRI findings.

    Time frame: 2 Years

  21. Need for systemic therapy later during disease course

    Stratum VI

    Time frame: 2 Years

  22. Identify possible risk factors for permanent consequences (PC)

    Time frame: 2 Years

07

Study locations

42 sites
08

Timeline

1 registry update since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimatedDate before it movedWhere the date was before it moved

The record gives a start of Nov 2016, a primary completion of Nov 2031 and a completion of Nov 2031. It does not say whether these dates are actual or estimated.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 10, 2026: primary completion Jul 2026 → Nov 2031 and completion Jul 2026 → Nov 2031.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 7, 2014
First posted
Jul 31, 2014
Start
Nov 2, 2016
Primary completionEst.
Nov 2031was Jul 2026
CompletionEst.
Nov 2031was Jul 2026
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Jul 2026→Nov 2031
Nov 10, 2026
Study completion
Jul 2026→Nov 2031
Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    Primary completion Jul 2026→Nov 2031
    Study completion Jul 2026→Nov 2031
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT02205762
Lead sponsor
North American Consortium for Histiocytosis
Collaborators
Histiocyte Society
Responsible party
Sponsor
First posted
Jul 31, 2014
Start date
Nov 2, 2016
Primary completion
Nov 2031 (estimated)
Completion
Nov 2031 (estimated)
Last update
Nov 10, 2026

Study contacts

Milen Minkov, MD, Ph.D
study chair · Children's Cancer Research Institute / St. Anna Children's Hospital
Carlos Rodriguez-Galindo, MD
study chair · North American Consortium for Histiocytosis

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Prednisone · Vinblastine · Mercaptopurine · Indomethacin · Methotrexate · Cytarabine · Cladribine · Immunoglobulins, Intravenous

Start the discussion